Access Erosion Signals & Value Frameworks

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics feel particularly urgent, given the convergence of access pressures and value framework shifts.

MarcusSame here. We're looking at HCA's profit warning signaling broader access erosion in US healthcare. Then subcutaneous Leqembi's approval and its HEOR implications. The FTC settlement with CVS Caremark over insulin pricing. And ICER's expansion of scientific advice into early-phase development.

SaraThat first one strikes me — the budget impact question there is one the field hasn't fully worked out yet. When systems report stress, how does that cascade to evidence requirements?

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning. This isn't just a single system's issue — it's a signal of systemic access erosion. When major hospital networks flag financial stress, it often prescribes pressure on formulary access and reimbursement for high-value therapies. The question is whether this triggers more stringent value demands.

SaraThat's one read — I'd frame it slightly differently. Payers aren't just reacting to system stress; they're actively using it as leverage in negotiations. We're seeing more references to 'system sustainability' in coverage decisions, which translates to higher evidence bars for novel therapies.

MarcusWhat strikes me about that is the timing. With IRA implementation accelerating, this could be the first real-world test of whether price negotiation authority correlates with tougher HTA requirements. If HCA's struggles lead to more coverage denials, it creates a vicious cycle.

SaraThe part that gives me pause is whether this is temporary or structural. Previous profit warnings haven't consistently altered reimbursement landscapes. But combined with Medicare Advantage Star Ratings changes, this might be different.

MarcusThat's fair, though I think payers would see it differently. They're already citing 'system strain' as a rationale for stepped-up cost-effectiveness reviews. We're seeing more requests for real-world evidence on comparative effectiveness even before approval.

SaraRight, and from the payer side, what's concerning is the lack of granularity. Are all therapies equally impacted? Or is this hitting orphan drugs and oncology hardest? The data doesn't yet distinguish.

MarcusExactly. Let's move to Leqembi's subcutaneous approval. This route change is significant — it addresses administration barriers, but the HEOR implications are complex.

SaraAbsolutely. The approval itself is straightforward, but the value proposition isn't. We now have two formulations of the same drug with different administration burdens. How do you model cost-effectiveness when the comparator isn't just placebo but the original intravenous version?

MarcusI wonder if that's the full picture though. The real challenge is demonstrating that the convenience translates to improved adherence or outcomes. Without that, the value proposition collapses. The FDA approval didn't require new efficacy data, so payers will demand real-world evidence on adherence.

SaraThat's precisely where the budget impact question becomes critical. If adherence improves marginally, the cost per QALY gained could be astronomical. We're in uncharted territory for combination products where the active ingredient is identical but delivery changes.

MarcusWhat strikes me is the precedent this sets. If Leqembi's subcutaneous version gets favorable reimbursement despite limited new data, it could open the door for similar reformulations of other high-cost therapies. The question is whether ICER or NICE will develop specific frameworks for these scenarios.

SaraThe part that gives me pause is the opportunity cost. If systems pay premium pricing for convenience without proven outcomes, it diverts resources from other innovations. Payers will be watching closely how this gets valued in Medicare Advantage formularies.

MarcusExactly. Now, the FTC settlement with CVS Caremark over insulin pricing. This is a significant moment for PBM practices and insulin access.

SaraThe settlement itself is straightforward — CVS agreed to $77 million in penalties over insulin pricing schemes. But what's interesting is how this exposes the opaque mechanics of PBM rebates and their impact on list prices versus net costs.

MarcusThat's one read — I'd frame it slightly differently. This signals the FTC's willingness to intervene in PBM practices that create artificial price inflation. For insulin, it's particularly notable because it's a mature market with established generics. The question is whether this shifts how manufacturers approach PBM contracting.

SaraWhat strikes me about that is the competition angle. The settlement claims CVS inflated insulin prices to increase rebate revenue. If proven, it suggests that PBMs are incentivizing higher list prices, which then triggers more aggressive formulary placement negotiations. That distorts the entire value proposition.

MarcusThe part that gives me pause is whether this changes payer behavior. If PBMs are seen as unreliable partners, payers might demand more transparency in rebate structures. That could lead to more direct contracting between manufacturers and health systems.

SaraRight, and from the payer side, what's concerning is the precedent for other therapeutic areas. If insulin can be scrutinized this way, what about biologics or gene therapies? The FTC's focus on 'unfair pricing' could extend beyond insulin.

MarcusExactly. Finally, ICER's expansion of scientific advice into early-phase development. This is a significant shift in HEOR strategy.

SaraThe announcement is clear: ICER will now provide advice in Phase I/II trials, focusing on evidence generation pathways. The stated goal is to de-risk development by aligning evidence generation with HTA requirements. But I'm skeptical about the practicality.

MarcusThat's fair, though I think industry would see this as a positive. Early alignment could prevent late-stage surprises. The question is whether ICER can provide meaningful advice when clinical data is so limited. How do you assess value with surrogate endpoints or small sample sizes?

SaraWhat strikes me about that is the resource implication. ICER's advice is already in high demand. Expanding to early phases could create bottlenecks. And how does this interact with FDA's breakthrough designation? There could be conflicting signals.

MarcusThe part that gives me pause is the methodology. ICER typically relies on comparative effectiveness data, which doesn't exist in early trials. Their advice might focus on endpoints or study design, but that's different from full value assessment. It risks being too prescriptive without flexibility for innovation.

SaraExactly. And from the payer side, what's concerning is whether this creates an uneven playing field. Companies that engage early might get preferential treatment, while those with novel mechanisms but less mature data could be disadvantaged. It might inadvertently favor me-too therapies over first-in-class.

MarcusThat's a valid concern. But the intention is good — to ensure evidence generation aligns with real-world needs. The challenge will be implementation.

SaraA lot to think about today. I'll be watching how HCA's financial stress translates to coverage decisions and whether it triggers new evidence requirements.

MarcusSame — and for me the thread running through today is how regulatory changes (Leqembi formulation, FTC settlement) and HTA shifts (ICER expansion) are converging to reshape value demonstration. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.